CH is defined as the presence of a somatic mutation associated with hematological malignancies, such as ASXL1, DNMT3A, JAK2, TET2, and TP53, without morphologic or clinical evidence of a hematological neoplasm [4,5]. This evidence concerns the gene DNMT3A and cyclic hematopoiesis.